| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10188697 | XELLIA PHARMS APS | Glycopeptide compositions |
Nov, 2035
(11 years from now) | |
| US10039804 | XELLIA PHARMS APS | Glycopeptide compositions |
Nov, 2035
(11 years from now) | |
| US11517609 | XELLIA PHARMS APS | Glycopeptide compositions |
Nov, 2035
(11 years from now) | |
| US10849956 | XELLIA PHARMS APS | Glycopeptide compositions |
Nov, 2035
(11 years from now) | |
| US11628200 | XELLIA PHARMS APS | Glycopeptide compositions |
Nov, 2035
(11 years from now) | |
Vancomycin Hydrochloride is owned by Xellia Pharms Aps.
Vancomycin Hydrochloride contains Vancomycin Hydrochloride.
Vancomycin Hydrochloride has a total of 5 drug patents out of which 0 drug patents have expired.
Vancomycin Hydrochloride was authorised for market use on 15 February, 2019.
Vancomycin Hydrochloride is available in solution;intravenous dosage forms.
Vancomycin Hydrochloride can be used as method of treating bacterial infections.
The generics of Vancomycin Hydrochloride are possible to be released after 06 November, 2035.
Drugs and Companies using VANCOMYCIN HYDROCHLORIDE ingredient
Market Authorisation Date: 15 February, 2019
Treatment: Method of treating bacterial infections
Dosage: SOLUTION;INTRAVENOUS
VANCOMYCIN HYDROCHLORIDE family patents
